MG53-based Therapy
Ischemia/Reperfusion Injury
Key Facts
About TRIM-edicine
TRIM-edicine is an early-stage biotech leveraging a proprietary protein platform, centered on MG53, to develop regenerative therapies for a broad range of conditions including tissue injury, muscular dystrophy, and aging. Founded in 2019 and led by a CEO with extensive investment experience and an MD/PhD VP of R&D, the company is seeking investors and development partners to advance its pipeline. While ambitious in scope, the company appears to be in a pre-clinical or early research stage, with its business model focused on therapeutic development and future partnerships.
View full company profileAbout TRIM-edicine
TRIM-edicine is an early-stage biotech leveraging a proprietary protein platform, centered on MG53, to develop regenerative therapies for a broad range of conditions including tissue injury, muscular dystrophy, and aging. Founded in 2019 and led by a CEO with extensive investment experience and an MD/PhD VP of R&D, the company is seeking investors and development partners to advance its pipeline. While ambitious in scope, the company appears to be in a pre-clinical or early research stage, with its business model focused on therapeutic development and future partnerships.
View full company profileAbout TRIM-edicine
TRIM-edicine is an early-stage biotech leveraging a proprietary protein platform, centered on MG53, to develop regenerative therapies for a broad range of conditions including tissue injury, muscular dystrophy, and aging. Founded in 2019 and led by a CEO with extensive investment experience and an MD/PhD VP of R&D, the company is seeking investors and development partners to advance its pipeline. While ambitious in scope, the company appears to be in a pre-clinical or early research stage, with its business model focused on therapeutic development and future partnerships.
View full company profileAbout TRIM-edicine
TRIM-edicine is an early-stage biotech leveraging a proprietary protein platform, centered on MG53, to develop regenerative therapies for a broad range of conditions including tissue injury, muscular dystrophy, and aging. Founded in 2019 and led by a CEO with extensive investment experience and an MD/PhD VP of R&D, the company is seeking investors and development partners to advance its pipeline. While ambitious in scope, the company appears to be in a pre-clinical or early research stage, with its business model focused on therapeutic development and future partnerships.
View full company profile